Data Surrounding Treatment for MSI-high Patients from ASCO 2024
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
Stay updated with breaking news from Msi High. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.
The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.
A urologic oncology fellow provides a comprehensive overview of systemic therapy options for patients with prostate cancer.
Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.
Experts on advanced ovarian cancer give detailed insights on the role of biomarker testing and identify important biomarkers.